Computational chemogenomics

Wiley Interdisciplinary Reviews: Computational Molecular Science

Volumn 1, Issue 1, 2011, Pages 57-67

  Jacoby, Edgar ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOINFORMATICS; INTERDISCIPLINARY RESEARCH; LIGAND-PROTEIN INTERACTION; MOLECULAR INFORMATION; PREDICTIVE MODELING; SMALL MOLECULES; STRUCTURE-BASED; SYSTEMATIC IDENTIFICATION;

BIOINFORMATICS; KNOWLEDGE BASED SYSTEMS;

LIGANDS;

EID: 80052885582     PISSN: 17590876     EISSN: 17590884     Source Type: Journal    
DOI: 10.1002/wcms.11     Document Type: Article

References (70)

1. Bredel M, Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet 2004, 5:262-275.
2. Lehmann J. Redesigning drug discovery. Nature 1996, 384(suppl):1-5.
3. Klabunde T. Chemogenomic approaches to drug discovery: similar receptors bind similar ligands. Br J Pharmacol 2007, 152:5-7.
4. Caron PR, Mullican MD, Mashal RD, Wilson KP, Su MS, Murcko MA. Chemogenomic approaches to drug discovery. Curr Opin Chem Biol 2001, 5:464-470.
5. Jacoby E. A novel chemogenomics knowledge-based ligand design strategy-application to G protein-coupled receptors. Quant Struct Act Relat 2001, 20:115-123.
6. Rognan D. Chemogenomic approaches to rational drug design. Br J Pharmacol 2007, 152:38-52.
7. Bajorath J. Computational analysis of ligand relationships within target families. Curr Opin Chem Biol 2008, 12:352-358.
8. Strausberg RL, Schreiber SL. From knowing to controlling: a path from genomics to drugs using small molecule probes. Science 2003, 300:294-295.
9. Williams AJ. Public chemical compound databases. Curr Opin Drug Discov Dev 2008, 11:393-404.
10. Schuffenhauer A, Zimmermann J, Stoop R, Van Der Vyver JJ, Lecchini S, Jacoby E. An ontology for pharmaceutical ligands and its application for in silico screening and library design. J Chem Inf Comput Sci 2002, 42:947-955.
11. Schuffenhauer A, Jacoby E. Annotating and mining the ligand-target chemogenomics knowledge space. Drug Discov Today BIOSILICO 2004, 2:190-200.
12. Brennan RJ, Nikolskya T, Bureeva S. Network and pathway analysis of compound-protein interactions. Methods Mol Biol 2009, 575:225-247.
13. Overington J. ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). Interview by Wendy A. Warr J Comput Aided Mol Des 2009, 23:195-198.
14. Garcia-Serna R, Ursu O, Oprea TI, Mestres J. iPHACE: integrative navigation in pharmacological space. Bioinformatics 2010, 26:985-986.
15. Wetzel S, Klein K, Renner S, Rauh D, Oprea TI, Mutzel P, Waldmann H. Interactive exploration of chemical space with Scaffold Hunter. Nat Chem Biol 2009, 5:581-583.
16. Renner S, van Otterlo WA, Dominguez Seoane M, Möcklinghoff S, Hofmann B, Wetzel S, Schuffenhauer A, Ertl P, Oprea TI, Steinhilber D, et al Bioactivity-guided mapping and navigation of chemical space. Nat Chem Biol 2009, 5:585-592.
17. Hopkins AL, Paolini GV. Chemogenomics in drug discovery-the druggable genome and target class properties. In: Mason, JS, ed. Comprehensive Medicinal Chemistry II, 4 (Computer-Assisted Drug Design). Amsterdam, the Netherlands: Elsevier; 2007, 421-433.
18. Ji HF, Kong DX, Shen L, Chen LL, Ma BG, Zhang HY. Distribution patterns of small-molecule ligands in the protein universe and implications for origin of life and drug discovery. Genome Biol 2007, 8:R176.
19. Strömbergsson H, Kleywegt GJ. A chemogenomics view on protein-ligand spaces. BMC Bioinformatics 2009, 10 (suppl 6):S13.
20. Balakin KV, Ivanenkov YA, Savchuk NP. Compound library design for target families. Methods Mol Biol 2009, 575:21-46.
21. Ning X, Rangwala H, Karypis G. Multi-assay-based structure-activity relationship models: improving structure-activity relationship models by incorporating activity information from related targets. J Chem Inf Model 2009, 49:2444-2456.
22. Jacob L, Hoffmann B, Stoven V, Vert JP. Virtual screening of GPCRs: an in silico chemogenomics approach. BMC Bioinformatics 2008, 9:363.
23. Savchuk NP, Balakin KV, Tkachenko SE. Exploring the chemogenomic knowledge space with annotated chemical libraries. Curr Opin Chem Biol 2004, 8:412-417.
24. Kuhn M, Campillos M, González P, Jensen LJ, Bork P. Large-scale prediction of drug-target relationships. FEBS Lett 2008, 582:1283-1290.
25. Stepanchikova AV, Lagunin AA, Filimonov DA, Poroikov VV. Prediction of biological activity spectra for substances: evaluation on the diverse sets of drug-like structures. Curr Med Chem 2003, 10:225-233.
26. Bender A, Young DW, Jenkins JL, Serrano M, Mikhailov D, Clemons PA, Davies JW. Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. Comb Chem High Throughput Screen 2007, 10:719-731.
27. Young DW, Bender A, Hoyt J, McWhinnie E, Chirn GW, Tao CY, Tallarico JA, Labow M, Jenkins JL, Mitchison TJ, et al Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol 2008, 4:59-68.
28. Nidhi, Glick M, Davies JW, Jenkins JL. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J Chem Inf Model 2006, 46:1124-1133.
29. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat Biotechnol 2006, 24:805-815.
30. Azzaoui K, Hamon J, Faller B, Whitebread S, Jacoby E, Bender A, Jenkins JL, Urban L. Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2007, 2:874-880.
31. Mestres J, Martín-Couce L, Gregori-Puigjané E, Cases M, Boyer S. Ligand-based approach to in silico pharmacology: nuclear receptor profiling. J Chem Inf Model 2006, 46:2725-2736.
32. Gregori-Puigjané E, Mestres J. Coverage and bias in chemical library design. Curr Opin Chem Biol 2008, 12:359-365.
33. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007, 25:197-206.
34. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, et al Predicting new molecular targets for known drugs. Nature 2009, 462:175-181.
35. Cases M, Mestres J. A chemogenomic approach to drug discovery: focus on cardiovascular diseases. Drug Discov Today 2009, 14:479-485.
36. Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. Data completeness - the Achilles heel of drug-target networks. Nat Biotechnol 2008, 26:983-984.
37. Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol Biosyst 2009, 5:1051-1057.
38. Stanton RV, Cao Q. Biological fingerprints. In: Mason JS, ed. Comprehensive Medicinal Chemistry II, 4 (Computer-Assisted Drug Design). Amsterdam, the Netherlands: Elsevier; 2007, 807-818.
39. Kauvar LM, Higgins DL, Villar HO, Sportsman JR, Engqvist-Goldstein A, Bukar R, Bauer KE, Dilley H, Rocke DM. Predicting ligand binding to proteins by affinity fingerprinting. Chem Biol 1995, 2:107-118.
40. Beroza P, Damodaran K, Lum RT. Target-related affinity profiling: Telik's lead discovery technology. Curr Top Med Chem 2005, 5:371-381.
41. Guba W, Green LG, Martin RE, Roche O, Kratochwil N, Mauser H, Bissantz C, Christ A, Stahl M. From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling. J Med Chem 2007, 50:6295-6298.
42. Johnson MA, Maggiora GM. Concepts and Applications of Molecular Similarity. New York: John Wiley & Sons; 1990.
43. Fliri AF, Loging WT, Thadeio PF, Volkmann RA. Biological spectra analysis: linking biological activity profiles to molecular structure. Proc Natl Acad Sci USA. 2005, 102:261-266.
44. Fliri AF, Loging WT, Thadeio PF, Volkmann RA. Biospectra analysis: model proteome characterizations for linking molecular structure and biological response. J Med Chem 2005, 48:6918-6925.
45. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 2008, 321:263-266.
46. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 2010, 6:343.
47. Bernasconi P, Chen M, Galasinski S, Popa-Burke I, Bobasheva A, Coudurier L, Birkos S, Hallam R, Janzen WP. A chemogenomic analysis of the human proteome: application to enzyme families. J Biomol Screen 2007, 12:972-982.
48. Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, Hemmerle H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys Acta 2004, 1697:243-257.
49. Debe DA, Hambly KP, Danzer JF. Structural informatics: chemogenomics in silico. In: Jacoby E, ed. Chemogenomics- Knowledge-based Approaches to Drug Discovery. London: Imperial College Press; 2006, 157-173.
50. Kuhn D, Weskamp N, Schmitt S, Hüllermeier E, Klebe G. From the similarity analysis of protein cavities to the functional classification of protein families using cavbase. J Mol Biol 2006, 359:1023-1044.
51. Weskamp N, Hüllermeier E, Klebe G. Merging chemical and biological space: structural mapping of enzyme binding pocket space. Proteins 2009, 76:317-330.
52. An J, Totrov M, Abagyan R. Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol Cell Proteomics 2005, 4:752-761.
53. Abagyan R, Kufareva I. The flexible pocketome engine for structural chemogenomics. Methods Mol Biol 2009, 575:249-279.
54. Kufareva I, Abagyan R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J Med Chem 2008, 51:7921-7932.
55. Pirard B. Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov Today 2007, 12:640-646.
56. Moriaud F, Doppelt-Azeroual O, Martin L, Oguievetskaia K, Koch K, Vorotyntsev A, Adcock SA, Delfaud F. Computational fragment-based approach at PDB scale by protein local similarity. J Chem Inf Model 2009, 49:280-294.
57. Oguievetskaia K, Martin-Chanas L, Vorotyntsev A, Doppelt-Azeroual O, Brotel X, Adcock SA, de Brevern AG, Delfaud F, Moriaud F. Computational fragment-based drug design to explore the hydrophobic sub-pocket of the mitotic kinesin Eg5 allosteric binding site. J Comput Aided Mol Des. (Epub ahead of print; June 17, 2009).
58. Steindl TM, Schuster D, Wolber G, Laggner C, Langer T. High-throughput structure-based pharmacophore modelling as a basis for successful parallel virtual screening. J Comput Aided Mol Des 2006, 20:703-715.
59. Gao Z, Li H, Zhang H, Liu X, Kang L, Luo X, Zhu W, Chen K, Wang X, Jiang H. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008, 9:104.
60. Rognan D. In silico screening of the protein structure repertoire and of protein families. In: Jacoby E, ed. Chemogenomics- Knowledge-based Approaches to Drug Discovery. London: Imperial College Press; 2006, 109-131.
61. Koch MA, Wittenberg LO, Basu S, Jeyaraj DA, Gourzoulidou E, Reinecke K, Odermatt A, Waldmann H. Compound library development guided by protein structure similarity clustering and natural product structure. Proc Natl Acad Sci USA 2004, 101:16721-16726.
62. Kaiser M, Wetzel S, Kumar K, Waldmann H. Biology-inspired synthesis of compound libraries. Cell Mol Life Sci 2008, 65:1186-1201.
63. Konrat R. The protein meta-structure: a novel concept for chemical and molecular biology. Cell Mol Life Sci 2009, 66:3625-3639.
64. Maréchal E. Chemogenomics: a discipline at the crossroad of high throughput technologies, biomarker research, combinatorial chemistry, genomics, cheminformatics, bioinformatics and artificial intelligence. Comb Chem High Throughput Screen 2008, 11:583-586.
65. Kubinyi H, Müller G, eds. Chemogenomics in Drug Discovery-A Medicinal Chemistry Perspective. Weinheim, Germany: Wiley-VCH; 2004.
66. Harris CJ, Stevens AP. Chemogenomics: structuring the drug discovery process to gene families. Drug Discov Today 2006, 11:880-888.
67. Scheiber J, Chen B, Milik M, Sukuru SC, Bender A, Mikhailov D, Whitebread S, Hamon J, Azzaoui K, Urban L, et al Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J Chem Inf Model 2009, 49:308-317.
68. Olaharski AJ, Gonzaludo N, Bitter H, Goldstein D, Kirchner S, Uppal H, Kolaja K. Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors. PLoS Comput Biol 2009, 5:e1000446.
69. Blum LC, Reymond JL. 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. J Am Chem Soc 2009, 131:8732-8733.
70. Jacoby E. Chemogenomics: Systemization of drug discovery. In: Abraham DJ, Rotella DP, eds. Burger's Medicinal Chemistry, Drug Discovery, and Development, Seventh Edition. Malden: John Wiley & Sons, Inc; 2010, 573-592.